J&J's Nipocalimab for FNAIT Gets on Fast Track for Approval
PharmaTech
MARCH 30, 2024
FDA granted fast track designation to nipocalimab, which J&J is developing for helping alloimmunized pregnant adults treat FNAIT, a rare disease that poses risk to the fetus or newborn.
Let's personalize your content